In yesterday’s Wall Street session, Vir Biotechnology Inc. (NASDAQ:VIR) shares traded at $14.35, up 12.99% from the previous session.
As of this writing, 9 analysts cover Vir Biotechnology Inc. (NASDAQ:VIR). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $100.00 and a low of $15.00, we find $24.50. Given the previous closing price of $12.70, this indicates a potential upside of 92.91 percent. VIR stock price is now -41.98% away from the 50-day moving average and -42.37% away from the 200-day moving average. The market capitalization of the company currently stands at $1.70B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 1 analysts who have given it a hold rating, whereas 7 have given it a buy rating. Brokers who have rated the stock have averaged $34.75 as their price target over the next twelve months.
With the price target reduced from $35 to $34, JP Morgan Upgraded its rating from Neutral to Overweight for Vir Biotechnology Inc. (NASDAQ: VIR).
In other news, SATO VICKI L, Director sold 18,000 shares of the company’s stock on Jun 30. The stock was sold for $443,916 at an average price of $24.66. Upon completion of the transaction, the Director now directly owns 1,315,351 shares in the company, valued at $18.88 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 30, 10% Owner SVF Endurance (Cayman) Ltd sold 700 shares of the business’s stock. A total of $17,577 was realized by selling the stock at an average price of $25.11. This leaves the insider owning 16,684,041 shares of the company worth $239.42 million. Insiders disposed of 15,986,200 shares of company stock worth roughly $229.4 million over the past 1 year. A total of 1.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VIR stock. A new stake in Vir Biotechnology Inc. shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $24,152,000. SOFINNOVA INVESTMENTS, INC. invested $9,436,000 in shares of VIR during the first quarter. In the first quarter, BRAIDWELL LP acquired a new stake in Vir Biotechnology Inc. valued at approximately $8,668,000. BALYASNY ASSET MANAGEMENT L.P. acquired a new stake in VIR for approximately $5,782,000. JUPITER ASSET MANAGEMENT LTD purchased a new stake in VIR valued at around $5,649,000 in the second quarter.
Friday morning saw Vir Biotechnology Inc. (NASDAQ: VIR) opened at $12.98. During the past 12 months, Vir Biotechnology Inc. has had a low of $12.56 and a high of $31.55. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.90, and a quick ratio of 4.90. The fifty day moving average price for VIR is $24.54 and a two-hundred day moving average price translates $24.87 for the stock.
The latest earnings results from Vir Biotechnology Inc. (NASDAQ: VIR) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$1.06, missing analysts’ expectations of -$0.87 by -0.19. This compares to $3.85 EPS in the same period last year. The net profit margin was -32.20% and return on equity was -7.10% for VIR. The company reported revenue of $62.96 million for the quarter, compared to $1.23 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -94.89 percent. For the current quarter, analysts expect VIR to generate $25.89M in revenue.
Vir Biotechnology Inc.(VIR) Company Profile
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
